TY - JOUR
T1 - HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype
AU - Shroff, Rukshana
AU - Speer, Thimoteus
AU - Colin, Sophie
AU - Charakida, Marietta
AU - Zewinger, Stephen
AU - Staels, Bart
AU - Chinetti-Gbaguidi, Giulia
AU - Hettrich, Inga
AU - Rohrer, Lucia
AU - O'Neill, Francis
AU - McLoughlin, Eve
AU - Long, David
AU - Shanahan, Catherine M.
AU - Landmesser, Ulf
AU - Fliser, Danilo
AU - Deanfield, John E.
PY - 2014/11
Y1 - 2014/11
N2 - Endothelial dysfunction begins in early CKD and contributes to cardiovascular mortality. HDL is considered antiatherogenic, but may have adverse vascular effects in cardiovascular disease, diabetes, and inflammatory conditions. The effect of renal failure on HDL properties is unknown. We studied the endothelial effects of HDL isolated from 82 children with CKD stages 2-5 (HDLCKD), who were free of underlying inflammatory diseases, diabetes, or active infections. Compared with HDL from healthy children, HDLCKD strongly inhibited nitric oxide production, promoted superoxide production, and increased vascular cell adhesion molecule-1 expression in human aortic endothelial cells, and reduced cholesterol efflux from macrophages. The effects on endothelial cells correlated with CKD grade, with the most profound changes induced by HDL from patients on dialysis, and partial recovery observed with HDL isolated after kidney transplantation. Furthermore, the in vitro effects on endothelial cells associated with increased aortic pulse wave velocity, carotid intima-media thickness, and circulating markers of endothelial dysfunction in patients. Symmetric dimethylarginine levels were increased in serum and fractions of HDL from children with CKD. In a longitudinal follow-up of eight children undergoing kidney transplantation, HDL-induced production of endothelial nitric oxide, superoxide, and vascular cell adhesion molecule-1 in vitro improved significantly at 3 months after transplantation, but did not reach normal levels. These results suggest that in children with CKD without concomitant disease affecting HDL function, HDL dysfunction begins in early CKD, progressing as renal function declines, and is partially reversed after kidney transplantation.
AB - Endothelial dysfunction begins in early CKD and contributes to cardiovascular mortality. HDL is considered antiatherogenic, but may have adverse vascular effects in cardiovascular disease, diabetes, and inflammatory conditions. The effect of renal failure on HDL properties is unknown. We studied the endothelial effects of HDL isolated from 82 children with CKD stages 2-5 (HDLCKD), who were free of underlying inflammatory diseases, diabetes, or active infections. Compared with HDL from healthy children, HDLCKD strongly inhibited nitric oxide production, promoted superoxide production, and increased vascular cell adhesion molecule-1 expression in human aortic endothelial cells, and reduced cholesterol efflux from macrophages. The effects on endothelial cells correlated with CKD grade, with the most profound changes induced by HDL from patients on dialysis, and partial recovery observed with HDL isolated after kidney transplantation. Furthermore, the in vitro effects on endothelial cells associated with increased aortic pulse wave velocity, carotid intima-media thickness, and circulating markers of endothelial dysfunction in patients. Symmetric dimethylarginine levels were increased in serum and fractions of HDL from children with CKD. In a longitudinal follow-up of eight children undergoing kidney transplantation, HDL-induced production of endothelial nitric oxide, superoxide, and vascular cell adhesion molecule-1 in vitro improved significantly at 3 months after transplantation, but did not reach normal levels. These results suggest that in children with CKD without concomitant disease affecting HDL function, HDL dysfunction begins in early CKD, progressing as renal function declines, and is partially reversed after kidney transplantation.
UR - http://www.scopus.com/inward/record.url?scp=84923945993&partnerID=8YFLogxK
U2 - 10.1681/ASN.2013111212
DO - 10.1681/ASN.2013111212
M3 - Article
C2 - 24854267
AN - SCOPUS:84923945993
SN - 1046-6673
VL - 25
SP - 2658
EP - 2668
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
IS - 11
ER -